Kevin Blinder, MD
Retina Specialist · Brentwood, MONPI 1669476560
Payments from drug & device makers
Across 487 payments — averaging $4584.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.2M
- Janssen Research & Development, LLC$385K
- Novartis$328K
- Regeneron Healthcare Solutions, Inc.$127K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$36K
- Bausch & Lomb Americas Inc.$35K
- plus $76K from 22 others
Across 8 payments — averaging $123.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$991
What the payments were for
- Consulting fees$39,24212%
- Speaking & faculty fees$245,91574%
- Travel & lodging$36,07311%
- Food & beverage$11,6654%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 123 | $1,246,085 |
| Janssen Research & Development, LLC | 36 | $385,329 |
| Novartis | 43 | $327,506 |
| Regeneron Healthcare Solutions, Inc. | 63 | $127,339 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 35 | $36,191 |
| Bausch & Lomb Americas Inc. | 48 | $34,555 |
| Astellas Pharma US Inc | 32 | $33,839 |
| Genentech USA, Inc. | 37 | $26,616 |
| Biogen | 7 | $8,163 |
| Eyepoint US, Inc. | 2 | $2,901 |
| AbbVie(2 entities) | 37 | $2,012 |
| Carl Zeiss Meditec USA, Inc. | 6 | $932 |
| Ocular Therapeutix, Inc. | 2 | $186 |
| Cardinal Health 110 LLC | 1 | $150 |
| Sight Sciences, Inc. | 1 | $142 |
| Rxsight Inc | 1 | $138 |
| Dutch Ophthalmic, USA | 1 | $135 |
| Regeneron | 1 | $119 |
| Apellis Pharmaceuticals, Inc. | 1 | $116 |
| Alcon | 1 | $94 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $35 |
| Carl Zeiss Meditec, Inc. | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $18 |
| Alimera Sciences, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$69,098
- EYLEA HD$57,732
- Izervay$33,352
- STELLARIS$30,942
- VABYSMO$26,172
- OPHTHALMIC INSTRUMENTS$18,356
- BEOVU$16,294
- VITESSE$14,487
- XIPERE$13,753
- Bausch + Lomb$11,484
- SURGICAL MISC$11,241
- STELLARIS PC$8,373
- LIGHT PIPES$8,373
- Laser Probes$7,500
- LOTEMAX SM$7,125
- STELLARIS ELITE$2,907
- EYP-1901$2,901
- VISUDYNE$2,625
- RETISERT$2,625
- VYZULTA$1,649
How this compares
$2,232,737 in reported general payments places this provider in the 95th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 59 | $21,136 |
| Ketorolac Tromethamine | 1,134 | $20,281 |
| Prednisolone Acetate | 476 | $18,125 |
| LumiganBimatoprost | 12 | $7,737 |
| Lotemax SmLoteprednol Etabonate | 25 | $6,381 |
| Bromfenac Sodium | 40 | $6,079 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $3,205 |
| BesivanceBesifloxacin Hcl | 13 | $2,930 |
| Loteprednol Etabonate | 21 | $2,169 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 123 | $2,054 |
| MoxifloxacinMoxifloxacin Hcl | 92 | $1,862 |
| Latanoprost | 171 | $1,497 |
| Brimonidine Tartrate | 103 | $1,446 |
| Dorzolamide Hcl | 84 | $1,347 |
| Timolol Maleate | 182 | $1,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate | $36,191 | $32,616118 claims |
| AbbVieLumigan, Combigan | $2,012 | $10,94228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 retina specialist providers in Missouri.
Other retina specialist in Brentwood
- Alia DurraniBrentwood$1.3M
- Sabin DangBrentwood$486K
- Athanasios PapakostasBrentwood$262K
- Bradley SmithBrentwood$113K
- Avinash HonasogeBrentwood$51K
- Barton BlackorbyBrentwood$31K
- Ollya FromalBrentwood$14K
- Nicholas IafeBrentwood$9K
- Dillan PatelBrentwood$5K
- William AndersonBrentwood$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.